{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:41Z","timestamp":1793806181276,"version":"4.6.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      In recent years, immunotherapy has significantly reshaped the pattern of non-small cell lung cancer (NSCLC) treatment. However, the issue of how to pinpoint potential responsive populations more accurately warrants immediate and focused attention. This study mainly explored the correlation between baseline peripheral blood biomarkers and prognosis in patients with advanced NSCLC undergoing immunotherapy. A retrospective analysis was performed on 139 patients diagnosed with advanced NSCLC who underwent first-line immunotherapy treatment between 2019 and 2022. Baseline demographic information and peripheral blood parameter data were collected. The Cox proportional hazards regression model was used to estimate hazard ratios and 95% confidence intervals to identify independent prognostic factors, while Kaplan\u2013Meier survival analysis with log-rank tests was applied to compare survival differences between groups. Finally, the predictive efficacy of biomarkers was assessed utilizing the receiver operating characteristic curve. C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were independent predictors for both progression-free survival (PFS) and overall survival (OS). Eosinophils\u2005&gt;\u20050.23\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, PLT (platelets)\u2005&gt;\u2005228\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, albumin\u2005\u2264\u200537.2g\/L, CRP\u2005&gt;\u20056.21mg\/L, or CEA\u2005&gt;\u20056.23ng\/ml was associated with poorer PFS. Meanwhile, (hemoglobin)\u2005\u2264\u2005132g\/L, platelets\u2005&gt;\u2005228\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, CRP\u2005&gt;\u20057.59mg\/L, or CEA\u2005&gt;\u20057.39ng\/ml may imply an inferior OS outcome. And the combination of CRP and CEA yielded areas under the curve with 0.675 and 0.656 for predicting PFS and OS, respectively. CRP and CEA hold the potential to predict the prognosis of advanced NSCLC patients undergoing first-line immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050902","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:01:32Z","timestamp":1790359292000},"page":"e50902","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral blood markers predict prognosis in patients with advanced non-small cell lung cancer receiving immunotherapy"],"prefix":"10.1097","volume":"105","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-3307","authenticated-orcid":false,"given":"Peng","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyue","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"P21","DOI":"10.1164\/rccm.20411P21","article-title":"Lung cancer.","volume":"204","author":"Lareau","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1186\/s12889-022-13281-y","article-title":"The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories.","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Public Health"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.jtho.2025.07.122","article-title":"Comprehensive genomic profiling of rare lung tumors: adenosquamous carcinoma and pulmonary carcinosarcoma.","volume":"20","author":"Zhou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41419-024-07075-w","article-title":"SOX4-BMI1 axis promotes non-small cell lung cancer progression and facilitates angiogenesis by suppressing ZNF24.","volume":"15","author":"Wen","year":"2024","journal-title":"Cell Death Dis"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer.","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer.","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-026-01791-w","article-title":"Current and future immunotherapies for NSCLC.","volume":"19","author":"Zhou","year":"2026","journal-title":"J Hematol Oncol"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41423-025-01347-x","article-title":"Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment.","volume":"22","author":"Ciancaglini","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jtho.2024.12.026","article-title":"In situ detection of programmed cell death protein 1 and programmed death ligand 1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC.","volume":"20","author":"Lindberg","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.xcrm.2024.101479","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"e003956","DOI":"10.1136\/jitc-2021-003956","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.","volume":"10","author":"Govindan","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/s41467-022-31926-9","article-title":"Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.","volume":"13","author":"Reda","year":"2022","journal-title":"Nat Commun"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","article-title":"The role of biomarkers in personalized immunotherapy.","volume":"10","author":"Sankar","year":"2022","journal-title":"Biomark Res"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"e004688","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.","volume":"10","author":"Hwang","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2021.11.021","article-title":"Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.","volume":"163","author":"Bryant","year":"2022","journal-title":"Lung Cancer"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12967-024-05142-6","article-title":"CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.","volume":"22","author":"Gelibter","year":"2024","journal-title":"J Transl Med"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.3390\/ijms24087577","article-title":"Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer.","volume":"24","author":"Pabst","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"2542068","DOI":"10.1080\/21645515.2025.2542068","article-title":"Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: efficacy, survival, and adverse events.","volume":"21","author":"Luan","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer.","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/cancers18101623","article-title":"In-treatment kinetics of peripheral blood immune markers in PD-L1 high non-small cell lung cancer and prognostic relevance for immunotherapy outcomes.","volume":"18","author":"Trontzas","year":"2026","journal-title":"Cancers (Basel)"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"869","DOI":"10.21873\/anticanres.14839","article-title":"Evaluation of serum biomarker CEA and Ca-125 as immunotherapy response predictors in metastatic non-small cell lung cancer.","volume":"41","author":"Clevers","year":"2021","journal-title":"Anticancer Res"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12967-026-08022-3","article-title":"Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets.","volume":"24","author":"Cao","year":"2026","journal-title":"J Transl Med"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"1385479","DOI":"10.3389\/fphar.2024.1385479","article-title":"Inflammation and cancer: friend or foe?","volume":"15","author":"Turizo-Smith","year":"2024","journal-title":"Front Pharmacol"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","article-title":"Inflammation: the incubator of the tumor microenvironment.","volume":"8","author":"Denk","year":"2022","journal-title":"Trends Cancer"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ymthe.2022.12.005","article-title":"CircRNAs regulate the crosstalk between inflammation and tumorigenesis: the bilateral association and molecular mechanisms.","volume":"31","author":"Qadir","year":"2023","journal-title":"Mol Ther"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"774823","DOI":"10.3389\/fonc.2021.774823","article-title":"C-reactive protein is an indicator of the immunosuppressive microenvironment fostered by myeloid cells in hepatocellular carcinoma.","volume":"11","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis.","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.4049\/jimmunol.174.11.6692","article-title":"Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.","volume":"174","author":"Stern","year":"2005","journal-title":"J Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:02:15Z","timestamp":1793804535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":33,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050902","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}